Cingulate Inc.
- CING
- NASDAQ
- Biotechnology
- ADHD Therapeutics
- Clinical-Stage Biopharma
$4.36
Today −0.68%Quote Oct 16, 2026, 08:00 PM UTC
−15.34%over the last month
Max drawdown −16.8%From 1-month high −16.8%3 months −4.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$63.4M
Quote Oct 16
Next earnings
Nov 12
Expected, not confirmed
Analyst target
$9.00
+106.4% from here
Floor
$4.28
1.9% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CINGPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
14
Founded
2012